When studying NAFLD, it is difficult to separate disease drivers from biomarkers; NAFLD has been associated with changes in cytokine profiles, insulin resistance, and dysfunctional lipid transport, but it is not fully known to what extent these factors initiate damage or are markers of damage. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.